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In 2015, a suspected cluster of two invasive meningo-
coccal disease (IMD) cases of serogroup W  Neisseria 
meningitidis  (MenW) occurred in elderly care home 
residents in England over 7 months; case inves-
tigations followed United Kingdom guidance. An 
incident control team reviewed epidemiological infor-
mation. Phenotyping of case specimens informed 
public health action, including vaccination and throat 
swabs to assess carriage. Whole genome sequencing 
(WGS) was conducted on case and carrier isolates. 
Conventional phenotyping did not exclude a micro-
biological link between cases (case 1 W:2a:P1.5,2 
and case 2 W:2a:NT). After the second case, 33/40 
residents and 13/32 staff were vaccinated and 19/40 
residents and 13/32 staff submitted throat swabs. Two 
MenW carriers and two MenC carriers were detected. 
WGS showed that MenW case and carrier isolates 
were closely related and possibly constituted a locally 
circulating strain. Meningococcal carriage, transmis-
sion dynamics and influence of care settings on IMD 
in older adults are poorly understood. WGS analyses 
performed following public health action helped to 
confirm the close relatedness of the case and circulat-
ing isolates despite phenotypic differences and sup-
ported actions taken. WGS was not sufficiently timely 
to guide public health practice.
Background
Neisseria meningitidis  (Nm) is a major cause of 
meningitis and septicaemia globally and is associated 
with significant mortality and long-term morbidity 
among survivors. The epidemiology of invasive 
meningococcal disease (IMD) is evolving and 
geographical and temporal trends change over time 
[1]. In England, IMD occurs most frequently in children 
under the age of 5 years with the highest incidence in 
infants aged less than 1 year [2]. In Europe and other 
industrialised countries, the incidence of serogroup 
B  N.  meningitidis  (MenB) has declined but remains a 
major cause of IMD [1]. In England, during the epide-
miological year 2014/15 (July–June, intended to cap-
ture winter peak of disease), MenB accounted for 58% 
(418/724) of laboratory-confirmed IMD (all ages) and 
74% (240/289) of laboratory-confirmed IMD in children 
less than 5 years old [2].
In contrast, meningococcal groups W (MenW) and Y 
(MenY) have historically been relatively uncommon 
causes of IMD, occurring more frequently in adults 
aged over 65 years who usually have underlying 
comorbidities. These capsular serogroups often have 
different clinical presentations from MenB, including 
pneumonia, septic arthritis, endocarditis and epiglot-
titis/supraglottitis [3]. In such cases, IMD may not be 
considered in the differential diagnosis and is only con-
firmed when  N. meningitidis  is unexpectedly isolated 
from blood culture or from culture of other sterile sites.
Although the overall incidence of laboratory-con-
firmed IMD in England has declined from 1,438 cases 
(3.8/100,000 population based on midyear population 
estimates [4]) in 2001/02 to 811 cases (1.5/100,000 
population) in 2015/16, the incidence of MenW IMD has 
increased every year from 2009 during this period [5]. 
In England, MenW cases nearly quadrupled from 55 in 
2012/13 to 211 in 2015/16 (Figure 1) when the highest 
incidence was in those aged under 5 years, followed by 
those over 65 years of age [2]. MenW cases in the latter 
group increased fourfold from 17 (0.2/100,000 popu-
lation) in 2012/13 to 75 (0.8/100,000 population) in 
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2015/16; the highest incidence in this age group was in 
those aged 85 years and older (1.3/100,000 in 2015/16) 
although case numbers were small. In 2012/13, all age 
case fatality ratio (CFR) in England was 13% for MenW 
IMD with the highest CFR in those aged 65 years or 
older (22%) [6]. 
The strain responsible for the increase in MenW IMD 
belongs to the sequence type (ST-)11 clonal complex 
(cc11) which is associated with multiple serogroups, 
in particular MenC and MenW, and has a tendency to 
cause outbreaks of relatively severe disease [7-9]. By 
2013/14, strains belonging to cc11 accounted for nearly 
all MenW cases in individuals aged 5–64 years and 
two-thirds of cases in those aged less than 5 years 
and 65 years and older [6]. The vast majority of MenW 
cc11 strains are indistinguishable by conventional typ-
ing schemes (PorB serotype 2a and PorA serosubtype 
P1.5,2) and belong to ST-11, as defined by seven-locus 
multilocus sequence typing (MLST) [10]. High-resolution 
core-genome MLST (cgMLST; based on ca 1,600 core 
genes), has recently revealed that cc11 comprises two 
main lineages, lineage 11.1 (including all major W:cc11 
strains and some serogroup B and C strains) and line-
age 11.2 (predominantly serogroup B and C strains). It 
also revealed considerable diversity among MenW cc11 
and demonstrated that the expanding United Kingdom 
(UK) strain belonged to the so-called South American-
strain sublineage having descended from a strain that 
emerged in South America in the early 2000s [11,12]. 
Subsequently, a descendant of the ‘original UK strain’ 
emerged in 2013 (the ‘2013-strain’) and has since 
expanded and spread to several European countries, 
Australia and Canada [13-15].
Laboratory confirmation of IMD and characterisation 
of the meningococcal strain responsible has important 
public health implications, as there is a need to offer 
timely antibiotic chemoprophylaxis and vaccination 
(depending on the serogroup). In addition to monitor-
ing cases for national surveillance, diagnosing IMD 
across all age groups is important to rapidly identify 
and manage clusters and outbreaks. Most reported 
IMD outbreaks and clusters have involved children 
and young adults (aged 0–25 years) and occurred in 
institutional settings including school and pre-school 
settings, universities and the military [16]. There are 
limited published reports of IMD clusters or outbreaks 
involving those aged over 25 years or outside these 
settings.
‘Extended’ MLST such as cgMLST provides considera-
ble additional resolving power for cluster and outbreak 
investigations where routine (such as 7 gene) schemes 
prove to be non-discriminatory [17]. The Meningitis 
Research Foundation Meningococcus Genome Library 
(MRF-MGL) [18] facilitates these analyses by provid-
ing online open-access to annotated draft genomes 
for all English, Welsh and Northern Irish case iso-
lates received by the Public Health England (PHE) 
Figure 1
Distribution of laboratory-confirmed MenW cases by age group and epidemiological year, England, 2010–2015 (n = 603)
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Meningococcal Reference Unit (MRU) since July 2010, 
alongside tools for their analysis.
Detection of suspected cluster of MenW IMD 
and initial public health response
In 2015, two cases of MenW IMD occurred in residents 
over 85 years old at a 46-bed elderly care home in North 
East England over a 7-month period; both cases had 
single bedrooms. According to national PHE guidance 
for the public health management of meningococcal 
disease, staff and other residents in nursing/residen-
tial homes are not routinely defined as close contacts 
following a single case of IMD [16]. Therefore, chemo-
prophylaxis was not provided to staff or residents dur-
ing the initial public health management of either case.
The prolonged interval (7 months) between the two 
cases raised questions about whether the infections 
were related and whether action was required to mini-
mise the risk of further cases in residents and staff. 
Here, we describe the case investigations, carriage 
data and use of whole genome sequencing (WGS) to 
inform public health action.
Methods
Laboratory investigations
Serogrouping, serotyping and serosubtyping were per-
formed as previously described [19]. Paired-end genome 
sequence analysis was performed using the Nextera 
XT library preparation kit (Illumina, Inc. San Diego, 
California) on the Illumina HiSeq 2500 (100bp read 
lengths; case isolates) or MiSeq (300bp read lengths; 
carrier isolates) platform. DNA input was 1ng of genomic 
DNA per isolate. The reads were assembled using 
Velvet (version 1.2.08) [20] in conjunction with Velvet 
optimiser (version v2.2.4) [21]. Genome assemblies 
were deposited on the PubMLST  Neisseriadatabase 
[22,23] and MRF-MGL where they underwent auto-
mated annotation at > 2,000 genomic loci including 
the seven MLST loci and 1,600 core genome loci. The 
isolates were compared with all remaining W:cc11 iso-
lates on the MRF-MGL (n = 387; accessed 24 Feb 2016) 
and an evolutionarily-distant B:cc11 lineage 11.2 refer-
ence strain (PubMLST ID 21361) in terms of 1,546 core 
genome loci using the PubMLST genome comparator 
tool. Incomplete loci (e.g. those that extend beyond the 
end of a contig) were ignored on a pairwise basis and 
paralogous loci were excluded from the analysis [6,11]. 
The resulting distance matrix (counting the number of 
different alleles, per pair of isolates, among the 1,546 
loci compared) was visualised as a Neighbor-net net-
work using SplitsTree4 (version 4.12.8).
Cluster investigation
Case 1 was admitted to hospital with acute respiratory 
distress and fever (temperature 41 °C). Bacteraemic 
pneumonia was diagnosed and the case died 6 days 
after onset of illness.  N. meningitidis  was isolated 
from blood cultures collected on admission and further 
typing data confirming  N. meningitidis  serogroup W, 
PorB serotype 2a and PorA serosubtype (P1.5,2) infec-
tion were received from the PHE MRU.
Case 2 was admitted to hospital with acute onset of 
fever, tachycardia and hypotension and was treated for 
respiratory sepsis unsuccessfully. The case died 7 days 
after onset of illness, which was 7 months after case 
1.  N. meningitidis  was isolated from blood cultures 
collected on admission and further typing confirming N. 
meningitidisserogroup W, PorB serotype 2a and PorA 
serosubtype (NT; non-typeable) was received from the 
MRU.
Following identification of MenW IMD in case 2, an 
assessment was undertaken to determine whether the 
cases could be linked and whether they might be part 
of a cluster.
Case definition
The case definition, based on PHE guidance [16], was 
a resident or member of staff with a clinical diagnosis 
of meningitis, septicaemia or other invasive disease 
and MenW detected by culture or molecular methods 
in a normally sterile site. Current UK guidance defines 
IMD clusters in educational settings as two or more 
confirmed cases of IMD with the same capsular group 
occurring within a 4-week period [16]. Although the 
temporal criterion of the cluster definition was not met 
in this situation, the occurrence of two cases of MenW 
IMD in residents of the same care home was extremely 
unusual. Given the limited knowledge of meningo-
coccal carriage in the elderly and IMD clusters within 
residential care settings, an incident control team (ICT) 
with representatives from the PHE North East Health 
Protection Team, the national PHE Immunisation team 
at the Centre for Infectious Disease Surveillance and 
Control (CIDSC) and PHE MRU was established to con-
sider further action.
Epidemiological investigation
The care home provides care for a maximum of 46 
residents (aged 65 years or older) including those with 
dementia-related conditions. At the time of investiga-
tion there were 40 residents (median age 83 years, 
range 66–98 years). Bedrooms are located over three 
floors and each resident has a single bedroom with 
en suite toilet. There are shared communal lounges on 
each floor; residents on the ground and first floors use 
the ground floor dining room. Accommodation and care 
for those with moderate to severe dementia-related 
conditions are provided in a separate self-contained 
unit on the second floor. Residents in the dementia unit 
do not have regular contact with those in other units, 
but the staff work between all parts of the care home.
Case 1 and case 2 had been resident in the care home 
for more than a year before the first onset of illness. 
Case 1 had been resident in the separate dementia unit 
for 11 months before onset, while case 2 was resident 
on the first floor. Both cases had been resident on the 
same floor for a 2-week period 11 months before the 
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onset in case 1. However, the cases had no contact 
with each other during this period nor for the remain-
der of their residencies spent on separate floors. The 
two cases shared bathrooms and communal dining 
areas with other residents on their respective floors 
and engaged in social activities during the day. Staff 
(median age 43 years, range 20–77 years) worked 
across all floors of the home and would have had con-
tact with both cases.
The ICT agreed that given the interval between onsets 
these could be sporadic unlinked infections. However, 
available phenotyping did not provide sufficient infor-
mation that isolates were different and the ICT was, 
therefore unable to determine that the cases were not 
microbiologically linked.
Control measures
Consequently, based on the case fatalities and uncer-
tainty about possible on-going carriage and transmis-
sion in the care home, the ICT decided that MenW 
vaccination should be offered to all residents and staff 
to protect against MenW disease. As the rationale for 
vaccination was based on the possibility of persisting 
carriage within the care home, the ICT made the prag-
matic decision that vaccination would be offered to all 
those who were resident or employed within the care 
home at the time of planned vaccination.
The ICT also agreed that the actions in the care home 
offered the opportunity to further the understanding 
of carriage in this setting and so agreed that throat 
swabs for  N. meningitidis  culture would be collected 
from residents and staff at the same time that vaccina-
tion was given. Vaccination and swabbing took place at 
the care home ca 12 weeks after the diagnosis of case 
2. Arrangements were also made so that staff could 
obtain vaccination from their family doctor if they were 
unable to attend the session.
 
Results
Vaccination and swabbing uptake
A single dose of MenACWY conjugate vaccine 
(Nimenrix®; Pfizer Inc) was offered to 40 residents 
and 32 staff; uptake was 83% (33/40) in residents and 
78% (25/32) in staff. Throat swabs were collected from 
48% (19/40) of residents and 40% (13/32) of staff. Of 
the 19/32 staff who did not submit throat swabs, one 
declined and the remainder did not attend the session.
Laboratory investigations
MenW was isolated in throat swabs from one resident 
in their 80s and one care worker in their 20s, while 
MenC was isolated from two care workers (Table). All 
isolates (two case isolates and four carrier isolates) 
underwent genome sequence analysis. The two MenC 
carrier isolates were identified as having PorA P1.5–
1,2–2 and belonging to ST-1157 (cc1157).
All four of the MenW isolates (two cases and two car-
riers) belonged to the UK-2013 strain of the South 
American strain sublineage (Figure 2). The Neighbor-
net network exclusively placed the isolate from case 
2 and the two carrier isolates into a distinct subline-
age differing from one another at between three and 
six loci (among the 1,546 compared). The isolate from 
case 1 exclusively formed a distinct sublineage and 
differed from the other three isolates at between 12 
and 19 loci. For comparison, the case 1 isolate differed 
from the other 387 isolates by between 11 and 239 loci 
(mean 51 loci, median 52 loci, SD 27 loci). Of the 12 iso-
lates that differed from the case 1 isolate at < 15 loci, six 
were isolated before the onset of case 1’s symptoms 
(isolates from 2014-15) and six afterwards (all during 
2015). These 12 isolates were widely distributed across 
England and Wales. The reported differences between 
the four case and carrier isolates were further evalu-
ated by performing BLAST searches and/or nt align-
ments of the corresponding alleles/isolates. Several 
reported differences were a result of an identical allele 
Table
Meningococcal case and carriage isolates including serogroup, phenotype and clonal complex, England, 2015 (n = 6)
IMD case/
carriage
Month of specimen 
collectiona, 2015 Staff/resident
Age 
group 
 
(years)
Serogroup
Phenotype Molecular type
PorA PorB Sequence type (clonal complex)
Case 1 0 Resident 80–90 W 2a (P1.5/P1.2/NT) ST-11 (cc11)
Case 2 7 Resident 90+ W 2a (NT/NT/NT) ST-11 (cc11)
Carriage 10 Resident 80–90 W 2a (P1.5 / P1.2 / NT) ST-11 (cc11)
Carriage 10 Staff 20–30 W 2a (P1.5 / P1.2 / NT) ST-11 (cc11)
Carriage 10 Staff 20–30 C NT (P1.5 / P1.2 / NT) ST-1157 (cc1157)
Carriage 10 Staff 30–40 C NT (P1.5 / P1.2 / NT) ST-1157 (cc1157)
Cc: clonal complex; IMD: invasive meningococcal disease; NT: not typable; ST: sequence type.
a Month of specimen collection from case 1 was set to 0. The following months indicate the number of months following the specimen 
collection from case 1.
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being assigned a full-length variant ID in one isolate 
and a truncated allele ID in the other (despite possess-
ing the full-length allele). In addition, several genes 
were erroneously classified as ‘missing’ due to frag-
mented assembly. After excluding erroneous differ-
ences, the two case isolates were found to differ at two 
loci while the case and carrier isolates collectively dif-
fered at between one and six loci. 
Discussion
We describe two cases of MenW IMD in elderly resi-
dents of a care home who presented with bacteraemic 
pneumonia due to a relatively rare but expanding hyper-
virulent clone. In the UK IMD is infrequently diagnosed 
in care home residents and two cases from the same 
home was unusual. Although the increase in MenW IMD 
in the UK was initially seen in adults aged 65 years and 
older [3], we believe that IMD may be underdiagnosed 
in this age group who frequently present with pneumo-
nia and symptoms other than meningitis. Streptococcus 
pneumoniae is the most common pathogen associated 
with community-acquired pneumonia (CAP) [24] and 
consequently there may be a low index of suspicion for 
IMD in adults aged 65 years and older with pneumonia.
Current UK guidelines for the management of CAP (that 
does not require hospitalisation) advise empirical treat-
ment with oral antibiotics; a microbiological investiga-
tion is not required [25]. Consequently, some patients 
may be treated for suspected CAP before being admit-
ted to hospital, which could affect the sensitivity of 
subsequent microbiological investigations to detect N. 
meningitidis and other pathogens. Meningococcal PCR 
testing is widely available in the UK, but it is not rou-
tinely conducted for CAP [25] and must be requested if 
IMD is clinically suspected [16].
The highest rates of meningococcal carriage have 
typically been reported in teenagers (15–19 years) and 
young adults (20–24 years) [26], but it is not known 
whether carriage in these age groups is responsible 
for transmission to older adults (65 years and older). It 
is also not known whether IMD in older adults occurs 
predominantly in those living in extended families i.e. 
exposure to children and teenagers (aged 0–19 years), 
or in institutions such as care homes, where transmis-
sion dynamics may be different. The cases we report 
here support this lack of information about the trans-
mission dynamics and risk of IMD in older adults as 
well as the influence of particular settings, such as 
residential care homes, on these factors.
We found carriage of two meningococcal serogroups in 
staff (MenW cc11 and MenC cc1157). The detection of 
MenC carriers was an unexpected finding, but cc1157 
carriage appears relatively common in the UK and 
has been reported among university students [27,28], 
including a multicentre study where cc1157 accounted 
for at least 449/8,462 (5.3%) of UK carrier isolates col-
lected from 1999 to 2001 [28]. However, cc1157 is not 
frequently associated with invasive disease; within the 
MRF-MGL (accessed 20 Mar 2019) cc1157 accounted for 
21/3,659 (0.6%) invasive disease cases in England, 
Wales and Northern Ireland, none of which were MenC 
or had PorA P1.5–1,2–2 [28]. Consequently, cc1157 car-
riage was not of particular clinical concern. Community 
MenC carriage in adults is not well-described as most 
carriage studies involve younger cohorts and pre-
ceded the introduction of the MenC vaccine. The role of 
meningococcal carriage in staff as a potential reservoir 
for transmission of infection to residents in long-term 
elderly care settings is not well understood and the rel-
evance of this finding is, therefore, unclear.
The 7-month interval between onsets and the differ-
ence in the PorA phenotype helped answer the question 
of whether these cases occurred due to the persistent 
communal carriage of the same strain or unrelated spo-
radic infections. WGS showed the case 2 and MenW 
carrier isolates to be very similar, suggesting possi-
ble on-going circulation of the strain responsible for 
the cases at the time of swabbing and supporting the 
Figure 2
Neighbor-net network of care home case and carrier 
isolates and MenW cc11 isolates from England, Wales and 
Northern Ireland, July 2010–December 2015
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public health actions taken. Given the national circula-
tion of similarly close strains, however, the possibility 
of separate introductions of the corresponding isolates 
could not be ruled out.
Close prolonged contact is required for transmission 
of meningococci [16,26,29] and secondary cases usu-
ally occur within 1 week of the primary case [30]. The 
UK guidance recommends that close contacts of index 
cases with suspected IMD are offered antibiotic chemo-
prophylaxis which provides highly effective short-term 
protection against secondary cases of all serogroups 
[16]. In the UK, MenC and MenB are included in the 
routine infant vaccination schedule, introduced in 
1999 and 2015, respectively [31]. MenC vaccine was 
offered to 13–14-year-olds and new university entrants 
aged ≤ 25 years until 2015 when, in response to the 
national MenW outbreak, it was replaced with the 
MenACWY conjugate vaccine for these age groups 
alongside a national outbreak control programme offer-
ing the vaccine to all 14-18 year olds and new university 
entrants [32]. In the UK, MenACWY conjugate vaccine 
is also offered to close contacts of confirmed cases 
of serogroup A, C, W or Y infection unless vaccinated 
within the preceding 12 months [32].
According to UK guidance at the time of the cluster [16], 
care home residents and staff were not routinely con-
sidered to be household-type contacts and this has 
been retained in updated guidance [32]. During the 
investigation, the question arose as to whether this 
advice should be reviewed. The limited evidence about 
transmission in residential care facilities for the elderly 
may reflect under-diagnosis and/or under-reporting in 
this age group. It may also be indicative of a genuinely 
low incidence of secondary transmission. In England, 
enhanced surveillance of IMD now includes questions 
about care home residence and prospective studies of 
possible transmission in this setting may be possible.
In our public health management, routine phenotyp-
ing did not exclude a microbiological link between 
cases while WGS, in conjunction with carriage screen-
ing, suggested possible wider circulation of the strain 
responsible for the second case. WGS is not yet suffi-
ciently timely to guide public health practice on its own 
and public health specialists must continue to act on 
the information available at the time, recognising that 
initial risk assessments may change in light of informa-
tion that becomes available at a later stage. This situ-
ation is not unique to the management of IMD or to the 
use of WGS.
The incidence of IMD caused by MenW:cc11 has 
increased in several European countries in recent 
years, with the highest number of cases in those 
aged ≥ 65 years [33]. The lack of understanding about 
meningococcal transmission dynamics and possi-
ble under-diagnosis of IMD in this age group and the 
management of cases in care settings are unlikely to 
be unique to the UK. This highlights the importance of 
ongoing European surveillance and sharing practical 
experience of using new laboratory techniques in pub-
lic health practice.
Acknowledgements 
This publication made use of the Neisseria Multi Locus 
Sequence Typing website (https://pubmlst.org/neisse-
ria/) sited at the University of Oxford. The development of 
this site has been funded by the Wellcome Trust and the 
European Union. It also made use of the Meningitis Research 
Foundation Meningococcus Genome Library (http://www.
meningitis.org/research/genome) developed by Public 
Health England, the Wellcome Trust Sanger Institute and the 
University of Oxford as a collaboration. The project is funded 
by Meningitis Research Foundation.
Conflict of interest
Ray Borrow reports grants for contract research on behalf 
of Public Health England (formerly the Health Protection 
Agency) for GlaxoSmithKline, Novartis Vaccines, Pfizer, 
and Sanofi Pasteur MSD, outside the submitted work. Jay 
Lucidarme has performed contract research on behalf of 
Public Health England for GlaxoSmithKline, Pfizer, and 
Sanofi Pasteur, outside the submitted work.
Authors’ contributions
The investigating team was Jonathan Lawler, Kirsty Foster, 
Lorna Smith, Ray Borrow, Steve Gray and Shamez Ladhani. 
Helen Campbell, Jay Lucidarme and Sydel Parikh contrib-
uted national epidemiology and surveillance data. Jonathan 
Lawler and Kirsty Foster drafted the paper. All authors re-
viewed and agreed the final version.
References
1. Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, et 
al. The Global Meningococcal Initiative meeting on prevention 
of meningococcal disease worldwide: Epidemiology, surveil-
lance, hypervirulent strains, antibiotic resistance and high-risk 
populations. Expert Rev Vaccines. 2019;18(1):15-30.  https://
doi.org/10.1080/14760584.2019.1557520  PMID: 30526162 
2. Public Health England (PHE). Invasive meningococcal disease 
in England: annual report for 2017 to 2018 supplementary data 
tables. London: PHE; 2018. Available from: https://www.gov.
uk/government/publications/meningococcal-disease-laborato-
ry-confirmed-cases-in-england-and-wales
3. Campbell H, Saliba V, Borrow R, Ramsay M, Ladhani SN. 
Targeted vaccination of teenagers following continued rapid 
endemic expansion of a single meningococcal group W clone 
(sequence type 11 clonal complex), United Kingdom 2015. Euro 
Surveill. 2015;20(28):21188.  https://doi.org/10.2807/1560-
7917.ES2015.20.28.21188  PMID: 26212140 
4. Office for National Statistics (ONS). Population Estimates 
for UK, England and Wales, Scotland and Northern Ireland: 
mid-2001 to mid 2010 and mid 2012 to mid-2016. Newport/
Titchfield/London: ONS; [accessed 22 Mar 2018]. https://www.
ons.gov.uk/peoplepopulationandcommunity/populationandmi-
gration/populationestimates/datasets/populationestimates-
forukenglandandwalesscotlandandnorthernireland
5. Public Health England (PHE). Continuing increase in meningo-
coccal group W (MenW) disease in England. Health Protection 
Report. London: PHE; 2015. Available from: https://assets.pub-
lishing.service.gov.uk/government/uploads/system/uploads/
attachment_data/file/409070/hpr0715_pge_d.pdf
6. Ladhani SN, Beebeejaun K, Lucidarme J, Campbell H, Gray S, 
Kaczmarski E, et al. Increase in endemic Neisseria meningitidis 
capsular group W sequence type 11 complex associated with 
severe invasive disease in England and Wales. Clin Infect Dis. 
2015;60(4):578-85.  https://doi.org/10.1093/cid/ciu881  PMID: 
25389259 
7www.eurosurveillance.org
7. Borrow R, Abad R, Trotter C, van der Klis FR, Vazquez JA. 
Effectiveness of meningococcal serogroup C vaccine pro-
grammes. Vaccine. 2013;31(41):4477-86.  https://doi.
org/10.1016/j.vaccine.2013.07.083  PMID: 23933336 
8. Mayer LW, Reeves MW, Al-Hamdan N, Sacchi CT, Taha MK, 
Ajello GW, et al. Outbreak of W135 meningococcal disease in 
2000: not emergence of a new W135 strain but clonal expan-
sion within the electophoretic type-37 complex. J Infect Dis. 
2002;185(11):1596-605.  https://doi.org/10.1086/340414  
PMID: 12023765 
9. Njanpop-Lafourcade BM, Parent du Châtelet I, Sanou O, Alonso 
JM, Taha MK. The establishment of Neisseria meningitidis 
serogroup W135 of the clonal complex ET-37/ST-11 as an 
epidemic clone and the persistence of serogroup A isolates in 
Burkina Faso. Microbes Infect. 2005;7(4):645-9.  https://doi.
org/10.1016/j.micinf.2005.01.003  PMID: 15823512 
10. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin 
R, et al. Multilocus sequence typing: a portable approach to 
the identification of clones within populations of pathogenic 
microorganisms. Proc Natl Acad Sci USA. 1998;95(6):3140-5.  
https://doi.org/10.1073/pnas.95.6.3140  PMID: 9501229 
11. Bratcher HB, Corton C, Jolley KA, Parkhill J, Maiden MCJ. A 
gene-by-gene population genomics platform: de novo as-
sembly, annotation and genealogical analysis of 108 repre-
sentative Neisseria meningitidis genomes. BMC Genomics. 
2014;15(1):1138.  https://doi.org/10.1186/1471-2164-15-1138  
PMID: 25523208 
12. Lucidarme J, Hill DMC, Bratcher HB, Gray SJ, du Plessis M, 
Tsang RSW, et al. Genomic resolution of an aggressive, 
widespread, diverse and expanding meningococcal serogroup 
B, C and W lineage. J Infect. 2015;71(5):544-52.  https://doi.
org/10.1016/j.jinf.2015.07.007  PMID: 26226598 
13. Lucidarme J, Scott KJ, Ure R, Smith A, Lindsay D, Stenmark 
B, et al. An international invasive meningococcal disease 
outbreak due to a novel and rapidly expanding serogroup 
W strain, Scotland and Sweden, July to August 2015. Euro 
Surveill. 2016;21(45):30395.  https://doi.org/10.2807/1560-
7917.ES.2016.21.45.30395  PMID: 27918265 
14. Booy R, Gentile A, Nissen M, Whelan J, Abitbol V. Recent 
changes in the epidemiology of Neisseria meningitidis sero-
group W across the world, current vaccination policy choices 
and possible future strategies. Hum Vaccin Immunother. 
2019;15(2):470-80.  https://doi.org/10.1080/21645515.2018.153
2248  PMID: 30296197 
15. Tsang RSW, Ahmad T, Tyler S, Lefebvre B, Deeks SL, Gilca R, 
et al. Whole genome typing of the recently emerged Canadian 
serogroup W Neisseria meningitidis sequence type 11 clonal 
complex isolates associated with invasive meningococcal dis-
ease. Int J Infect Dis. 2018;69:55-62.  https://doi.org/10.1016/j.
ijid.2018.01.019  PMID: 29414677 
16. Health Protection Agency (HPA). Guidance for the public 
health management of meningococcal disease in the UK. 
London: HPA; 2012. Available from: https://webarchive.na-
tionalarchives.gov.uk/20170207134452/https://www.gov.uk/
government/publications/meningococcal-disease-guidance-
on-public-health-management
17. Chatt C, Gajraj R, Hawker J, Neal K, Tahir M, Lawrence M, et 
al. Four-month outbreak of invasive meningococcal disease 
caused by a rare serogroup B strain, identified through the 
use of molecular PorA subtyping, England, 2013. Euro Surveill. 
2014;19(44):20949.  https://doi.org/10.2807/1560-7917.
ES2014.19.44.20949  PMID: 25394258 
18. Meningitis Research Foundation (MRF). MRF Meningococcus 
Genome Library (MGL). [Accessed 24 Feb 2016 and 20 Mar 
2019]. Available from: http://www.meningitis.org/research/
genome
19. Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, 
et al. Meningococcal Reference Unit. Epidemiology of menin-
gococcal disease in England and Wales 1993/94 to 2003/04: 
contribution and experiences of the Meningococcal Reference 
Unit. J Med Microbiol. 2006;55(Pt 7):887-96.  https://doi.
org/10.1099/jmm.0.46288-0  PMID: 16772416 
20. Zerbino DR, Birney E. Velvet: algorithms for de novo short 
read assembly using de Bruijn graphs. Genome Res. 
2008;18(5):821-9.  https://doi.org/10.1101/gr.074492.107  
PMID: 18349386 
21. Zerbino DR. Using the Velvet de novo assembler for short-
read sequencing technologies. Curr Protoc Bioinformatics. 
2010;Chapter 11:5. PMID: 20836074 
22. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial popula-
tion genomics: BIGSdb software, the PubMLST.org website and 
their applications. Wellcome Open Res. 2018;3:124.  https://
doi.org/10.12688/wellcomeopenres.14826.1  PMID: 30345391 
23. Meningitis Research Foundation (MRF) Meningococcus Genome 
Library. (PubMLST) [Accessed 31 May 2019]. Available from htt-
ps://pubmlst.org/bigsdb?db=pubmlst_neisseria_mrfgenomes
24. Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: 
burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45-
51.  https://doi.org/10.1111/1469-0691.12461  PMID: 24313448 
25. National Institute for Health and Care Excellence (NICE). 
Pneumonia in adults: diagnosis and management Clinical 
guideline [CG191]. London: NICE; 2014. Available from: https://
www.nice.org.uk/guidance/CG191
26. Trotter CL, Gay NJ, Edmunds WJ. The natural his-
tory of meningococcal carriage and disease. Epidemiol 
Infect. 2006;134(3):556-66.  https://doi.org/10.1017/
S0950268805005339  PMID: 16238823 
27. Bidmos FA, Neal KR, Oldfield NJ, Turner DPJ, Ala’Aldeen DAA, 
Bayliss CD. Persistence, replacement, and rapid clonal expan-
sion of meningococcal carriage isolates in a 2008 university 
student cohort. J Clin Microbiol. 2011;49(2):506-12.  https://
doi.org/10.1128/JCM.01322-10  PMID: 21123536 
28. Ibarz-Pavón AB, Maclennan J, Andrews NJ, Gray SJ, Urwin R, 
Clarke SC, et al. Changes in serogroup and genotype preva-
lence among carried meningococci in the United Kingdom dur-
ing vaccine implementation. J Infect Dis. 2011;204(7):1046-53.  
https://doi.org/10.1093/infdis/jir466  PMID: 21881120 
29. Caugant DA, Maiden MCJ. Meningococcal carriage and disease-
-population biology and evolution. Vaccine. 2009;27(Suppl 
2):B64-70.  https://doi.org/10.1016/j.vaccine.2009.04.061  
PMID: 19464092 
30. Ladhani SN, Cordery R, Mandal S, Christensen H, Campbell 
H, Borrow R, et al. PHE VaPIBI Forum Members. Preventing 
secondary cases of invasive meningococcal capsular group B 
(MenB) disease using a recently-licensed, multi-component, 
protein-based vaccine (Bexsero(®)). J Infect. 2014;69(5):470-
80.  https://doi.org/10.1016/j.jinf.2014.07.002  PMID: 
25043395 
31. Public Health England (PHE). Meningococcal: the green 
book, chapter 22. Meningococcal immunisation infor-
mation for public health professionals. Immunisation 
against infectious disease. London: PHE; 2016. Available 
from: https://www.gov.uk/government/collections/
immunisation-against-infectious-disease-the-green-book
32. Public Health England (PHE). Guidance for the public 
health management of meningococcal disease in the UK 
Updated February 2018. London: PHE; 2018. Available 
from: https://www.gov.uk/government/collections/
meningococcal-disease-guidance-data-and-analysis
33. Krone M, Gray S, Abad R, Skoczyńska A, Stefanelli P, van 
der Ende A, et al. Increase of invasive meningococcal se-
rogroup W disease in Europe, 2013 to 2017. Euro Surveill. 
2019;24(14):1800245.  https://doi.org/10.2807/1560-7917.
ES.2019.24.14.1800245  PMID: 30968827
License, supplementary material and copyright
This is an open-access article distributed under the terms of 
the Creative Commons Attribution (CC BY 4.0) Licence. You 
may share and adapt the material, but must give appropriate
credit to the source, provide a link to the licence and indicate 
if changes were made. 
Any supplementary material referenced in the article can be 
found in the online version.
This article is copyright of the authors or their affiliated in-
stitutions, 2019.
